PIK3CA-Related Overgrowth Spectrum clinical trials at UC Davis
1 research study open to eligible people
Showing trials for
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
open to eligible people ages 2-100
This study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth spectrum (PROS).
Sacramento, California and other locations
Last updated: